239 related articles for article (PubMed ID: 2565807)
21. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
22. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.
Galisteo ML; Dikic I; Batzer AG; Langdon WY; Schlessinger J
J Biol Chem; 1995 Sep; 270(35):20242-5. PubMed ID: 7657591
[TBL] [Abstract][Full Text] [Related]
24. Biological and biochemical activities of a chimeric epidermal growth factor-Elk receptor tyrosine kinase.
Lhoták V; Pawson T
Mol Cell Biol; 1993 Nov; 13(11):7071-9. PubMed ID: 8413296
[TBL] [Abstract][Full Text] [Related]
25. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins.
Osherov N; Gazit A; Gilon C; Levitzki A
J Biol Chem; 1993 May; 268(15):11134-42. PubMed ID: 8098709
[TBL] [Abstract][Full Text] [Related]
27. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene.
Di Marco E; Pierce JH; Knicley CL; Di Fiore PP
Mol Cell Biol; 1990 Jun; 10(6):3247-52. PubMed ID: 1971420
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
29. Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses.
Pandiella A; Lehvaslaiho H; Magni M; Alitalo K; Meldolesi J
Oncogene; 1989 Nov; 4(11):1299-305. PubMed ID: 2573029
[TBL] [Abstract][Full Text] [Related]
30. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
Liu SM; Carpenter G
J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.
Hynes NE; Taverna D; Harwerth IM; Ciardiello F; Salomon DS; Yamamoto T; Groner B
Mol Cell Biol; 1990 Aug; 10(8):4027-34. PubMed ID: 2196443
[TBL] [Abstract][Full Text] [Related]
32. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.
Kokai Y; Myers JN; Wada T; Brown VI; LeVea CM; Davis JG; Dobashi K; Greene MI
Cell; 1989 Jul; 58(2):287-92. PubMed ID: 2568888
[TBL] [Abstract][Full Text] [Related]
33. A chimeric, ligand-binding v-erbB/EGF receptor retains transforming potential.
Riedel H; Schlessinger J; Ullrich A
Science; 1987 Apr; 236(4798):197-200. PubMed ID: 3494307
[TBL] [Abstract][Full Text] [Related]
34. Constitutive association of EGF receptor with the CrkII-23 mutant that inhibits transformation of NRK cells by EGF and TGF-beta.
Ota S; Kizaka-Kondoh S; Hashimoto Y; Nishihara H; Nagashima K; Kurata T; Okayama H; Matsuda M
Cell Signal; 1998 Apr; 10(4):283-90. PubMed ID: 9617486
[TBL] [Abstract][Full Text] [Related]
35. The role of the neu oncogene product in cell transformation and normal development.
Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
[TBL] [Abstract][Full Text] [Related]
36. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Donato NJ; Ince C; Rosenblum MG; Gallick GE
J Cell Biochem; 1989 Nov; 41(3):139-57. PubMed ID: 2482293
[TBL] [Abstract][Full Text] [Related]
37. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
[TBL] [Abstract][Full Text] [Related]
38. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.
Velu TJ; Beguinot L; Vass WC; Willingham MC; Merlino GT; Pastan I; Lowy DR
Science; 1987 Dec; 238(4832):1408-10. PubMed ID: 3500513
[TBL] [Abstract][Full Text] [Related]
39. 2-Aminopurine abolishes EGF- and TPA-stimulated pp33 phosphorylation and c-fos induction without affecting the activation of protein kinase C.
Mahadevan LC; Wills AJ; Hirst EA; Rathjen PD; Heath JK
Oncogene; 1990 Mar; 5(3):327-35. PubMed ID: 2107492
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene.
Sikes RA; Chung LW
Cancer Res; 1992 Jun; 52(11):3174-81. PubMed ID: 1350510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
